In the Prospective Comparison of ARNI With ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure (PARADIGM-HF) trial, median B-type natriuretic peptide (BNP) and NT-proBNP concentration was measured after 4 to 6 weeks, 8 to 10 weeks, and 9 months of treatment with sacubitril/valsartan. This evidence concerns the gene NPPB and hydrops fetalis.